Key Stats for Abbott Laboratories Stock
- Past-Week Performance: 1.7%
- 52-Week Range: $105 to $141
- Current Price: $112
What Happened to Abbott Laboratories Stock?
Abbott Laboratories (ABT) shares are trading near $112, pulling back modestly as investors weigh a series of high-profile developments across the company’s sprawling medical device and diagnostics portfolio.
The FDA linked 860 serious injuries and 7 deaths to faulty glucose readings from certain FreeStyle Libre 3 and Libre 3 Plus sensors as of January 7, 2026, dragging on sentiment, though Abbott says it has identified and resolved the root cause.
Despite the recall overhang, Abbott’s Q4 2025 earnings showed the Medical Devices segment growing 10.5%, with CGM sales exceeding $7.5 billion for the year and Electrophysiology delivering double-digit growth even before the U.S. Volt PFA launch began its limited market release.
The market is increasingly viewing Abbott as a multi-engine growth company rather than a CGM-dependent story, with Rhythm Management, Structural Heart, and EPD all accelerating alongside the pending Exact Sciences acquisition that adds a high-growth cancer diagnostics vertical.
The Nutrition segment remains the clearest near-term drag, with management guiding for continued weakness in H1 2026 before a recovery, a dynamic that trimmed full-year organic sales guidance to a 7% midpoint versus prior Street consensus closer to 7.5%.
Meanwhile, longer term, the combination of Volt’s U.S. ramp, a potential non-insulin CGM reimbursement expansion from CMS, and the Exact Sciences close in early 2026 gives Abbott several distinct catalysts that could drive EPS well above the guided 10% growth floor.
Where is the ABT Stock Headed?
With the Volt PFA launch underway in the U.S., the Exact Sciences deal closing imminently, and a potential CMS reimbursement expansion for non-insulin CGM users on the horizon, Abbott enters 2026 with more identifiable growth catalysts than at any point in recent years.
The fundamental case for Abbott Laboratories stock is anchored by Street estimates projecting 2026 revenue of $47.9 billion (+8.1% YoY) and normalized EPS of $5.68 (+10.2%), with EBIT margins expected to expand to 23.8%, continuing a multi-year trajectory of disciplined operational improvement.
However, Wall Street is broadly constructive, with 16 Buys and 6 Outperforms among 25 analysts as of February 19, 2026, and a mean price target of $133.39, implying roughly 19% upside from the current price of $112.19.
The target range is wide, spanning from a low of $113 to a high of $158, reflecting genuine uncertainty around Nutrition’s recovery timeline, the Exact Sciences integration, and the pace of PFA market share gains against Medtronic.
Therefore, a mid-case DCF valuation model pegs Abbott’s fair value at $182 by December 2030, implying a 62.2% total return and a 10.5% annualized IRR from current levels, making the current price look like a compelling entry point on a multi-year basis.
The primary risk is multiple compression, as the model assumes P/E contracts at a 2.6% CAGR, meaning Abbott must grow earnings fast enough to overcome valuation de-rating, a tough ask if Nutrition drags longer than the guided two quarters or the Libre 3 recall damages CGM brand equity.
At $112, Abbott trades well below both analyst consensus and model fair value, making it look undervalued for patient investors willing to look through near-term Nutrition headwinds and recall noise toward a 2026 and 2027 pipeline that is among the richest in large-cap MedTech.
Value Any Stock in Under 60 Seconds (It’s Free)
With TIKR’s new Valuation Model tool, you can estimate a stock’s potential share price in under a minute.
All it takes is three simple inputs:
- Revenue Growth
- Operating Margins
- Exit P/E Multiple
From there, TIKR calculates the potential share price and total returns under Bull, Base, and Bear scenarios so you can quickly see whether a stock looks undervalued or overvalued.
If you’re not sure what to enter, TIKR automatically fills in each input using analysts’ consensus estimates, giving you a quick, reliable starting point.
